Sodium-glucose co-transporter 2
Jump to navigation
Jump to search
solute carrier family 5 (sodium/glucose cotransporter), member 2 | |
---|---|
Identifiers | |
Symbol | SLC5A2 |
Alt. symbols | SGLT2 |
Entrez | 6524 |
HUGO | 11037 |
OMIM | 182381 |
RefSeq | NM_003041 |
UniProt | P31639 |
Other data | |
Locus | Chr. 16 p11.2 |
Overview
Sodium-dependent glucose cotrasporter 2 are a family of glucose transporter "expressed in the luminal membrane of the proximal kidney tubules"[1]. They contribute to renal glucose reabsorption.
Pharmacology
Inhibitors
- Canagliflozin
- Dapagliflozin
- Empagliflozin
- Gliflozin
Inhibitors improve glycemic control[2] and may reduce clinical outcomes[3].
References
- ↑ Anonymous 2015, co-transporter 2 Sodium-glucose co-transporter 2. Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E; et al. (2013). "Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis". Ann Intern Med. 159 (4): 262–74. doi:10.7326/0003-4819-159-4-201308200-00007. PMID 24026259. Review in: Ann Intern Med. 2014 Jan 21;160(2):JC10
- ↑ Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S; et al. (2015). "Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes". N Engl J Med. doi:10.1056/NEJMoa1504720. PMID 26378978.
External links
- Sodium-Glucose+Transporter+2 at the US National Library of Medicine Medical Subject Headings (MeSH)